(UroToday.com) Patients with newly-diagnosed metastatic hormone-sensitive prostate cancer have a plethora of treatment options available. In addition to a number of systemic therapies, data from the HORRAD trial and STAMPEDE-RT have demonstrated a survival benefit to the addition of local, prostate-directed radiotherapy for men with low-volume metastatic disease.